XF-73 data maturing, like a fine wine
Destiny have released additional endpoint analyses after the positive headline announcement of the Phase 2b study of XF-73 for the prevention of staphylococcal post-surgical infections in March 2021. The new analyses looked at the same endpoint, but out to six days after surgery and confirmed the durability of XF-73’s effect on S.aureus carriage.The recent analysis of the secondary endpoints at later timepoints improved XF-73’s profile even further. This data showed that XF-73-treated patients had a valuable, sustained S.aureus knock-down at the time points of one hour, then two and six days after surgery. This may be even more impressive than the previous primary endpoint data which was measured just prior to surgery, because of post-operative wound dressing and observation that could allow S.aureus carriers more chances to infect wounds from their nasal colonisation.
The advantages of Destiny’s other Phase 3-ready product NTCD-M3 – a single species microbiome drug for the prevention of Clostridiodes difficile infections (CDIs) – are also continuing to improve against the competitors misfortunes. Our previous note on M3 had in fact highlighted its better safety and efficacy against the competition.
We have maintained financial forecasts and valuation at 335p / share but recognise that Destiny’s profile, with two Phase 3-ready anti-infective and microbiome assets, is improving with the release of its own data, and the missteps of its competitors.
Seres Therapeutics is a microbiome therapeutics platform company developing a class of biological drugs, which it refers to as Ecobiotic? microbiome therapeutics. SER-287 is being developed to treat ulcerative colitis, or UC. SER-109 is designed to reduce recurrences of Clostridium difficile infection, or CDI, a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by treating the dysbiosis of the colonic microbiome. In addition, using its microbiome therapeutics platform, the company is developing product candidates to treat diseases including SER-301, a rationally designed, fermented UC candidate, and SER-401, a microbiome therapeutic candidate.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.